Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Smeland, S.
Right arrow Articles by Holte, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smeland, S.
Right arrow Articles by Holte, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:1072-1078, 2004
© 2004 European Society for Medical Oncology

Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens

Background: Burkitt's/Burkitt-like lymphoma (BL/BLL) are highly aggressive lymphomas mainly affecting children and young adults. We report the results in adolescent and adult patients with the use of three successive regimens.

Patients and methods: Forty-nine patients aged 15–70 years admitted to the Norwegian Radium Hospital in the period 1982–2001 with a diagnosis of BL/BLL on histological review and who were given chemotherapy with curative intent are included in this analysis. Up to 1987 patients were given doxorubicin-based chemotherapy supplemented with intravenous and intrathecal methotrexate (MmCHOP). From 1987 to 1994, patients who obtained complete remission upon this regimen were consolidated with high-dose therapy with stem-cell support (MmCHOP + HDT). In 1995 we introduced as frontline therapy the German Berlin–Frankfurt–Munster (BFM) regimen.

Results: By intention to treat analyses, the progression-free survival rates for patients who received MmCHOP (n=13), MmCHOP + HDT (n=17) or BFM therapy (n=19) are 30.8%, 70.6% and 73.7%, respectively. In the groups of patients who received either the BFM regimen or MmCHOP + HDT, all patients who obtained complete remission upon induction therapy are continuously disease free. There was no treatment-related death.

Conclusions: BL/BLL in adolescents and adults can successfully be treated with 5-day blocks of intensified chemotherapy such as the BFM regimen or CHOP/methotrexate-based chemotherapy consolidated with high-dose therapy. Using the BFM regimen, continuous remissions are obtained without additional myeloablative chemotherapy.

S. Smeland1, A. K. Blystad1, S. O. Kvaløy1, I. M. Ikonomou2, J. Delabie2, G. Kvalheim1, J. Hammerstrøm3, G. F. Lauritzsen1 and H. Holte1,*

Departments of 1 Medical Oncology; 2 Pathology, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo; 3 Department of Medicine, Section of Haematology, University Hospital, Trondheim, Norway

*Correspondence to: Dr H. Holte, Department of Medical Oncology, The Norwegian Radium Hospital, University of Oslo, Montebello, 0310 Oslo, Norway. Tel: +47-22-93-48-82; Fax: +47-22-52-55-59;; Email: harald.holte{at}klinmed.uio.no

Key words: BFM chemotherapy, Burkitt's lymphoma, high-dose therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 haematolHome page
I. Salaverria, A. Zettl, S. Bea, E. M. Hartmann, S. S. Dave, G. W. Wright, E.-J. Boerma, P. M. Kluin, G. Ott, W. C. Chan, et al.
Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma
Haematologica, September 1, 2008; 93(9): 1327 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Klapper, M. Szczepanowski, B. Burkhardt, H. Berger, M. Rosolowski, S. Bentink, C. Schwaenen, S. Wessendorf, R. Spang, P. Moller, et al.
Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials
Blood, August 15, 2008; 112(4): 1374 - 1381.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. S. Dave, K. Fu, G. W. Wright, L. T. Lam, P. Kluin, E.-J. Boerma, T. C. Greiner, D. D. Weisenburger, A. Rosenwald, G. Ott, et al.
Molecular diagnosis of Burkitt's lymphoma.
N. Engl. J. Med., June 8, 2006; 354(23): 2431 - 2442.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. T. Lim, R. Karim, B. N. Nathwani, A. Tulpule, B. Espina, and A. M. Levine
AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre-Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard Chemotherapy
J. Clin. Oncol., July 1, 2005; 23(19): 4430 - 4438.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.